RenovoRx (NASDAQ:RNXT) is a biopharmaceutical company focused on developing innovative treatments for cancer, particularly pancreatic and bile duct cancer. The firm is committed to advancing its flagship product, RenovoGem, a therapy that combines chemotherapy with RenovoRx's patented intra-arterial delivery system. This unique approach aims to maximize the efficacy of cancer treatment by delivering drugs directly to the tumor site, thus reducing systemic side effects and improving patient outcomes. Among its projects, RenovoRx is involved in several clinical studies designed to test the safety and effectiveness of its treatments in patients. The company's primary goals include pushing the boundaries of cancer treatment to provide more effective solutions, obtaining regulatory approval for its products, and ultimately improving the quality of life for patients battling these challenging diseases.